PFS Partners’s IGM Biosciences IGMS Stock Holding History

PFS Partners’s Portfolio IGMS Stock Details IGMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-230	Closed	-$5.23K	–	384
2022 Q3	$5.23K	Hold	230	–	–	0.01%	247
2022 Q2	$4.15K	Buy	+230	New	+$4.1K	﹤0.01%	260

Other funds holding IGMS

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PFS Partners's IGMS Position: Q4 2022 in Review

PFS Partners sold out of IGM Biosciences (IGMS) in Q4 2022, closing a stake of 230 shares — an estimated $5.23K sold.

PFS Partners first reported a position in IGMS in Q2 2022 and held it in 2 quarters. The position peaked at $5.23K in Q3 2022. 82 funds tracked by Wall St. Rank hold IGMS as of Q4 2022.

PFS Partners reported no remaining IGM Biosciences position as of Q4 2022 after selling out during the quarter.
PFS Partners sold 230 IGM Biosciences shares in Q4 2022, an estimated $5.23K.
PFS Partners first reported a position in IGM Biosciences in Q2 2022 and held it in 2 quarters.
PFS Partners's IGM Biosciences position peaked at $5.23K in Q3 2022.
82 funds tracked by Wall St. Rank held IGM Biosciences as of Q4 2022.

Based on PFS Partners's 13F filing for Q4 2022, filed 1 Dec 2023.